DC
OCUL icon

Diametric Capital’s Ocular Therapeutix OCUL Stock Holding History

Diametric Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-125,000
Closed -$1.06M – 625
2026
Q1 		$1.06M Buy
+125,000
New +$1.19M 0.28% 90
2020
Q1 		– Sell
-107,298
Closed -$424K – 151
2019
Q4 		$424K Buy
+107,298
New +$373K 0.31% 87

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital's OCUL Position: Q2 2026 in Review

Diametric Capital sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 125,000 shares — an estimated $1.06M sold.

Diametric Capital first reported a position in OCUL in Q4 2019 and held it in 2 quarters. The position peaked at $1.06M in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Diametric Capital reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 125,000 Ocular Therapeutix shares in Q2 2026, an estimated $1.06M.
  • Diametric Capital first reported a position in Ocular Therapeutix in Q4 2019 and held it in 2 quarters.
  • Diametric Capital's Ocular Therapeutix position peaked at $1.06M in Q1 2026.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.